Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan
Ustekinumab is a monoclonal antibody indicated for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA). The biosimilar was developed and manufactured by Biocon Biologics and received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in December 2024.
This launch follows a settlement and licensing agreement signed in April 2024 between Biocon Biologics and Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, allowing commercialization of Ustekinumab in Japan after regulatory approval.
Biocon Biologics had earlier launched the biosimilar Ustekinumab in the United States and Europe in February 2025, expanding its availability to help patients manage chronic inflammatory conditions.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Titagarh Rail secures contract worth Rs 1,598.55 crore for Mumbai Metro Rail Project from NCC
Titagarh Rail Systems Limited has bagged a major contract worth approximately ₹1,598.55 crore as a specialized subcontractor in the Mumbai Metro Rail Project. The Letter of Acceptance (LOA) was issued by NCC Limited on August 2, 2025. Under this high-value contract, Titagarh Rail will be responsible for the design, manufacturing, supply, installation, integration, testing, and commissioning of 108 metro coaches—comprising 18 trains with six cars each—for Mumbai Metro Line 6, which will run from Swami Samarth Nagar to Vikhroli (Eastern Express Highway). In addition to delivering the rolling stock, the contract also includes a two-year Defect Liability Maintenance Period, followed by five years of comprehensive maintenance, further expanding the company's long-term role in one of Mumbai's key metro corridors. The execution timeline for the design-build portion is 104 weeks, after which the maintenance phases will kick in. The project has been awarded by NCC Limited, a domestic entity, under the broader development plans of the Mumbai Metropolitan Region Development Authority (MMRDA). Titagarh Rail clarified that this is not a related-party transaction and no promoter or group company has any stake in NCC Limited. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
a day ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Business Upturn
a day ago
- Business Upturn
HPCL signs 10-year LNG supply deal with Abu Dhabi's ALNG
By Aman Shukla Published on August 2, 2025, 20:14 IST Hindustan Petroleum Corporation Limited (HPCL) has entered into a strategic agreement with Abu Dhabi Gas Liquefaction Company (ALNG), a subsidiary of ADNOC Gas, for the long-term supply of Liquefied Natural Gas (LNG) over a 10-year period. The agreement, signed under a Heads of Agreement (HOA), marks a major step in bolstering India's energy security and advancing HPCL's clean energy goals. As per the agreement, HPCL will receive LNG at the newly commissioned Chhara LNG Terminal in Gujarat. The imported LNG will be used to meet the fuel requirements of HPCL's refineries, its City Gas Distribution (CGD) network, and for supplying to downstream customers. ALNG, part of ADNOC Gas, is a globally recognized integrated gas processing and sales company. This collaboration highlights the strengthening energy partnership between India and the UAE, while also supporting India's broader transition toward cleaner fuels. This 10-year LNG procurement deal is expected to play a key role in meeting India's growing energy demands while reducing reliance on more carbon-intensive fuels. It reinforces HPCL's long-term commitment to sustainability and a greener energy future. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
